Evidence for a defect in fatty acid uptake by adipose tissue of patients with hypertriglyceridaemia

LARS A. CARLSON, GÖRAN WALLDIUS, AND ANDERS G. OLSSON

From the Department of Geriatrics, University of Uppsala, and King Gustaf Vth Research Institute, Stockholm, Sweden

Professor Robinson has described the importance of lipoprotein lipase (clearing factor lipase) for the initial phase in the clearance of plasma triglycerides, whether exogenous and present as chylomicrons or endogenous and present as very-low-density lipoprotein (VLDL). It acts by splitting off the fatty acids which are then taken up by the cells. Our interest in hypertriglyceridaemia was extended to the later phases of the clearance process as a result of an unusual case described below.

Case A.A. was a man aged 50 with massive hypertriglyceridaemia, with plasma levels sometimes exceeding 150 mmol/l (approximately 12 500 mg/100 ml) compared with the normal of about 1-2 mmol/l. Initially, fasting plasma looked like cream and most of the triglyceride was present in the chylomicrons, i.e., in particles with Sf > 400, but there was also elevation of the VLDL with Sf < 400 (table I). The hyperlipidaemia is thus best classified as type V (World Health Organization Memorandum, 1970).

An example of the large fluctuation in plasma triglyceride concentration that occurred with variations in the diet is given in figure 1. The patient was extremely fat-sensitive and on a fat-rich diet plasma triglycerides increased almost to 200 mmol/l (or about 17 500 mg/100 ml). However, a fat-poor diet, and even starvation, did not bring the level below 50 mmol/l, and over a period of several years the level has usually fluctuated between about 50 and 150 mmol/l. Although alimentary lipoaemia was exaggerated it was rapidly cleared by intravenous heparin, the free fatty acid concentration in the plasma increasing at the same time. Moreover, the plasma lipolytic activity 45 minutes after intravenous heparin (Boberg and Carlson, 1964) has been assayed on several occasions, with plasma triglyceride concentrations varying from 6 to 90 mmol/l depending on treatment (see below), and the results have always fallen in the range 73-124 mmol glycerol/minute/l compared with our normal range of 60 to 140 (Boberg, 1972). These findings suggest a defect in removal of triglycerides in the presence of normal postheparin lipoprotein lipase activity.

A point of great interest is the therapeutic response to treatment with nicotinic acid (fig 2). Not only did the plasma triglyceride concentration fall completely, though slowly, to normal during treatment, but it remained normal for many weeks after stopping treatment, after which it increased slowly. A similar, though somewhat slower, response was also obtained with nicotinamide, which usually has no effect on hyperlipidaemia, and once again the level of triglyceride remained almost normal for several weeks when treatment was stopped. The plasma cholesterol behaved in the same way as the triglycerides, as would be expected from the reduction in lipoprotein molecules (chylomicrons and VLDL) which contain not only triglycerides but also cholesterol. A complete plasma lipoprotein analysis of this case before and after treatment is given elsewhere (Carlson, Fröberg, and Öro, 1972).

These observations turned our attention to possible explanations for a triglyceride clearance defect other than low lipoprotein lipase activity, including the possibility of a defect within the cell. The transport of fatty acids into the cell after hydrolysis of plasma triglycerides by lipoprotein

---

**Table I** Distribution of fasting plasma triglycerides of case A.A. in different fractions of the very low density lipoproteins (VLDL) separated at density 1006 according to Gustafson, Alaupovic, and Furman (1965)

<table>
<thead>
<tr>
<th>Fraction</th>
<th>Total VLDL</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>Sr. range</td>
<td>&gt;5000</td>
</tr>
<tr>
<td></td>
<td>5000</td>
</tr>
<tr>
<td>Triglyceride concentration (mmol/l)</td>
<td>42.8</td>
</tr>
</tbody>
</table>

1 Fractions A and B comprise the chylomicrons.

2 Supported by grants from the Swedish Medical Research Council (197x-204).

1 mmol/l = 88.5 mg/100 ml for triolein.
Evidence for a defect in fatty acid uptake by adipose tissue of patients with hypertriglyceridaemia

Fig 1 Variation in fasting plasma lipids with diet in case A.A.

Fig 2 Effect of nicotinic acid on fasting plasma lipids in case A.A.
esterification of the fatty acids but also glucose metabolism because \( \alpha \)-glycerophosphate, which is needed for the esterification of the fatty acids, is mainly formed from glucose. Figure 3 summarizes these reactions which culminate in the esterification of the fatty acids with \( \alpha \)-glycerophosphate and their deposition as triglycerides. It is interesting to note, in view of the patient's response to both nicotinic acid and nicotinamide, that the conversion of dihydroxyacetone phosphate (DHAP) to \( \alpha \)-glycerophosphate (\( \alpha \)-GP) is NAD dependent. Both nicotinic acid and its amide may be precursors of NAD.

In order to explore the possibility that a defect in the processes involved in the uptake and esterification of fatty acids existed in our patient the uptake of fatty acids by adipose tissue was studied in vitro; 200 mg of adipose tissue was incubated for two hours in a medium containing \(^3\)H-labelled fatty acids and \(^{14}\)C-labelled glucose (macro-method). After incubation the tissues were homogenized, the lipids separated, the glycerides hydrolysed, and the radioactivities determined in the fatty acid and glycerol moieties (Carlson, Eriksson, and Walldius, 1973). The findings in the patient both before and after treatment with nicotinic acid are given in Table II together with values obtained similarly in control subjects. Before treatment the rate of incorporation of both fatty acid and glucose into adipose tissue glycerides was clearly below the lowest level observed in all control subjects. Both increased, three and six-fold respectively, to within the normal range after the plasma triglycerides had been restored to near normal.

Table II  Fatty acid and glucose incorporation into adipose tissue in vitro obtained with macromethod (mean \( \pm \) SEM, range)

<table>
<thead>
<tr>
<th></th>
<th>Controls(^1)</th>
<th>Case A.A.(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal lipidaemic ( \alpha )-lipidaemic</td>
<td>Before ( \alpha )-lipidaemic</td>
</tr>
<tr>
<td>(^{1})H-fatty acid</td>
<td>(130 \pm 30) (70-290)</td>
<td>(140 \pm 30) (50-240)</td>
</tr>
<tr>
<td>(^{14})C-glucose</td>
<td>(310 \pm 70) (180-650)</td>
<td>(170 \pm 20) (100-240)</td>
</tr>
</tbody>
</table>

\(^1\)Tissue from controls was obtained during surgery for gallbladder disease, and from case A.A. after local anaesthesia. Controls are classified as normo- or hyperlipidaemic on the basis of blood analyses performed some weeks after operation; hyperlipidaemia was only minor, and in no case was the plasma opalescent.

\(^3\)Before and after treatment refers to treatment with nicotinic acid; this was continued for two months and reduced the plasma triglycerides to near normal.

---

### Fig 3  Schematic representation of the uptake of triglyceride fatty acids by the adipocyte.

1. Membrane transport, hexokinases
2. Phosphofructokinase
3. Glycerophosphate dehydrogenase, NADH/ NAD
4. Lipoprotein lipase
5. FA activation
6. Triglyceride synthesis
normal by treatment with nicotinic acid.

To summarize, in this patient there is a defect in the clearance of triglycerides from plasma. There appears to be no deficiency in lipoprotein lipase activity, but when the patient is hyperlipidaemic there is a defective uptake of fatty acids by adipose tissue; this reverts to within the normal range when plasma lipids return to near normal after treatment with nicotinic acid.

These observations led us to study the fatty acid incorporation into adipose tissue (FIAT) in vitro in other cases of hyperlipidaemia. A microtechnique was developed requiring only 20 mg of adipose tissue obtained by fine needle biopsy, its precision being ±10%. The tissue is obtained by a single needle biopsy so that repeated biopsies can be taken.

The results in a group of patients with hyperlipidaemia are given in figure 4. The FIAT values in hyperlipidaemia such as low lipoprotein lipase activity and increased triglyceride secretion from the liver. Another interesting feature of the adipose tissue of hyperlipidaemic subjects is that there is evidence of increased fat-mobilizing lipolysis as shown by measurement of glycerol release (fig 6). This is particularly the case in type IV.

normal subjects vary over a wide range. Five patients with type V hyperlipidaemia all had subnormal FIAT levels. In type II B, type III, and type IV all characterized by hypertriglyceridaemia, we also found subnormal values for FIAT, while in the normotriglyceridaemic type IIA the values, as expected, were in the normal range. Figure 5 shows a similar picture for glucose incorporation into adipose tissue (GLIAT) but the differences are less pronounced.

It should be noted that several of the patients with type IV hyperlipoproteinaemia had FIAT as well as GLIAT values within the normal range. This suggests that defects other than low FIAT may be causing the

![Fig 4 Fatty acid incorporation into adipose tissue (FIAT) in patients with different types of hyperlipidaemia. Each symbol represents one patient. Thick bars indicate the mean, the hatched line the lowest normal value. Micro-method. * values indicate significance of difference from normals (N). □ Men; ○ women.]

![Fig 5 Incorporation of glucose into adipose tissue (GLIAT) in patients with different types of hyperlipidaemia. Symbols as for figure 4.]

![Fig 6 Lipolysis as measured by glycerol release in patients with different types of hyperlipidaemia. Symbols as for fig 4, except that the hatched line indicates the highest normal value.]

These studies have indicated a new metabolic defect—low FIAT—in adipose tissue of patients with different types of hypertriglyceridaemia. A low FIAT may possibly cause hypertriglyceridaemia by slowing down the clearance of plasma triglycerides as a result of impaired fatty acid uptake in adipose tissue.
This new aspect on hypertriglyceridaemia may also explain a previously puzzling difference between type I and type V hyperlipoproteinaemia. In spite of the fact that both chylomicrons and VLDL are believed to be cleared from plasma by the same mechanisms (fig 3) it is only the former lipoprotein family which is elevated in type I while both are raised in type V. The finding of low FIAT in type V now appears to afford an explanation for these differences. In type I the defective clearing of chylomicrons is due to lack of or low lipoprotein lipase activity (fig 3), and hence no fatty acids are split off to be transported to the liver and there converted to VLDL. In type V, however, lipoprotein lipase activity is present and fatty acids can be split off; as there is a low FIAT function, such fatty acids are likely to spill over into the blood and be transported to the liver for conversion to VLDL which may be expected to appear in the blood in increased amount.

In summary, the finding of a patient with massive hypertriglyceridaemia and normal postheparin lipoprotein lipase activity who responded to both nicotinic acid and nicotinamide with normalization of plasma triglycerides led us to look for other mechanisms of hypertriglyceridaemia than low lipoprotein lipase activity. The patient was found to have a low FIAT (fatty acid incorporation into adipose tissue) which was corrected by treatment with nicotinic acid. In further studies a low FIAT was demonstrated in several types of hypertriglyceridaemia. Since removal of plasma triglycerides requires the following processes: (1) hydrolysis to fatty acids by lipoprotein lipase and (2) uptake and esterification of the fatty acids (FIAT), we suggest that hypertriglyceridaemia may, among other things, be caused by a low lipoprotein lipase activity and/or a low FIAT function.

References


Evidence for a defect in fatty acid uptake by adipose tissue of patients with hypertriglyceridaemia.
L A Carlson, G Walldius and A G Olsson

*J Clin Pathol* 1973 s1-5: 48-52
doi: 10.1136/jcp.s1-5.1.48

Updated information and services can be found at:
http://jcp.bmj.com/content/s1-5/1/48.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/